$20M GSK milestone for Pozen
North Carolina, USA-based drug developer Pozen has received a total of $20.0 million in milestone payments from UK drug major GlaxoSmithKline for the US Food and Drug Administration approval of and GSK's intent to commercialize Treximet (sumatriptan and naproxen sodium) for the acute treatment of migraine in adults. This is the first and only product designed to target multiple mechanisms of migraine by combining a triptan and an anti-inflammatory pain reliever in a single tablet.
John Plachetka, Pozan's chief executive, said: "we are extremely pleased that the FDA has approved Treximet and are very excited that GSK has already begun the process to commercialize the drug with expected availability in pharmacies by mid-May."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze